Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing, has released the unaudited financial statements for the Q2 FY25.

In the second quarter of FY25, Supriya Lifescience witnessed remarkable growth in its revenue, reporting 18.6 % year-over-year increase, reaching Rs. 166.1 crore compared to Rs. 140.1 crore in Q2 FY24.

EBITDA for Q2 FY25 stood at Rs. 64.72 crore, with an EBITDA Margin of 39.0%, as opposed to an EBITDA of Rs. 31.75 crore in Q2 FY24 with an EBITDA margin of 22.7%. This marks a growth of 103.8% YoY.

The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24.

Dr. Satish Wagh, Executive Chairman & WTD, Supriya Lifescience Ltd, commenting on the results, said, “Our commitment to innovation through R&D is paving the way for sustained growth and expansion. With the commissioning of our advanced R&D lab at Lote Parshuram and the upcoming Ambernath facility, we’re focusing on new product development and CMO/CDMO opportunities to complement our existing portfolio.

“Expanding our global presence across key regions, we're also working closely with regulatory and sales teams to acquire new customers, particularly in regulated markets. Our recent exclusive 10-year contract with a leading European firm underscores our capabilities in handling complex chemical processes, setting the stage for similar opportunities. As we enhance our infrastructure, including increasing capacity at Lote Parshuram to 1,020 KL by Q3 FY25, we’re building a foundation for a stronger future."

According to the company’s release analgesic and anaesthetic segment led the business growth in Q2 contributing 54.9% to the revenue vs 50.0% in Q2FY24. Anti-Asthmatic segment contributed 9.2% compared to 7.2%.  

European markets now contribute 45% of our business revenue in H1FY25 up from 39% in H1FY24.